27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ:CRSP) exa-cel for sickle cell disease and transfusion-dependent beta-thalassemia (TDT).
The FDA has granted priority review for exa-cel in SCD with a PDUFA date of December 8, 2023, and standard review for TDT with a PDUFA date of March 30, 2024.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
William Blair resumes coverage with an Outperform rating. William Blair analyst says the acceptance of the BLA for exa-cel with priority review for SCD is positive, given it presents a larger market opportunity between the two indications and will be the first CRISPR-based therapy to be reviewed by the FDA for approval.
It notes the lack of priority review in TDT as unfortunate but does not see it ultimately affecting the probability of exa-cel's approval in TDT or its commercial success.
The analyst speculates that the standard review process for TDT could be because there is already an FDA-approved gene therapy for TDT from bluebird bio Inc (NASDAQ:BLUE), decreasing the urgency for novel therapeutics for the indication.
JMP Securities writes that the exa-cel BLA acceptance by the FDA represents a major milestone ahead of potential approvals that will have read across to all gene editing names.
It maintains the Market Outperform rating on CRISPR Therapeutics. It increases the price target to $74 from $70 and points to a rapidly approaching regulatory decision in the EU that could be accretive to CRSP shares in the short term.
Truist writes that the news is a significant relief.
Price Action: CRSP shares are down 1.20% at $61.84 on the last check Friday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.